Anatabine

Last Updated: September 28 2022

Anatabine is an alkaloid compound found in tobacco and plants in the nightshade family, which includes eggplant and peppers. Anatabine possesses anti-inflammatory properties but further research is needed to determine if supplementation is practical.

Anatabine is most often used for

Summary

Anatabine is an alkaloid found in tobacco and other plants in the nightshade family.

Anatabine is being researched for its anti-inflammatory properties. Preliminary evidence suggests it may be useful to treat autoimmune diseases and Alzheimer’s disease.

Unfortunately, current research uses doses that are significantly higher than the anatabine supplements available on the market. Oral studies tend to use a dose of 1.6mg/kg of bodyweight for people, which translates to dose between 68-110mg for a 150lb person. One human study even failed to find anti-inflammatory effects at a dose that was 6 – 12 times higher than the doses found in today’s anatabine supplements.

Anatabine’s main mechanism works by inhibiting the signal transducer and activator of transcription 3 protein (STAT3), which inhibits a protein responsible for DNA transcription, called nuclear factor kappa-light-chain-enhancer of activated B cells (nF-kB). Both Boswellia serrata and Feverfew have a similar mechanism.

Due to limitation of anatabine supplements on the market, it is not a practical anti-inflammatory supplement.

What else is Anatabine known as?
Note that Anatabine is also known as:
  • Anatabloc (Brand Name)
Dosage information

Animal research on anatabine used an oral dose of 12.5 – 20mg/kg of bodyweight in mice, for the purpose of autoimmune diseases. This suggests a preliminary human dose of:

• 70-110 mg for a 150lb person

• 90-150 mg for a 200lb person

• 110-180 mg for a 250lb person

These dosages are based on preliminary animal evidence, not human studies. Anatabine supplementation cannot be recommended at this time due to a lack of human evidence for its effects.

Join our supplement information course

Enter your email for a FREE five-day course on supplements. Get only the information that’s 100% backed by science. We take an independent and unbiased approach to figure out what works (and what’s a waste of time and money).

Examine is the only 100% independent company in the nutrition and supplement industry. While everyone else sells supplements and works with sponsors, we exclusively analyze research.

    The only 100% independent company. While everyone sells supplements, we only analyze research.

    Examine Database: Anatabine
    What works and what doesn't?

    Unlock the full potential of Examine

    Get started

    Don't miss out on the latest research

    Become an Examine Insider for FREE to stay on top of the latest nutrition research, supplement myths, and more

      References
      4.^Paris D, Beaulieu-Abdelahad D, Bachmeier C, Reed J, Ait-Ghezala G, Bishop A, Chao J, Mathura V, Crawford F, Mullan MAnatabine lowers Alzheimer's Aβ production in vitro and in vivoEur J Pharmacol.(2011 Nov 30)
      5.^Paris D, Patel N, Quadros A, Linan M, Bakshi P, Ait-Ghezala G, Mullan MInhibition of Abeta production by NF-kappaB inhibitorsNeurosci Lett.(2007 Mar 19)
      6.^Paris D, Ganey NJ, Laporte V, Patel NS, Beaulieu-Abdelahad D, Bachmeier C, March A, Ait-Ghezala G, Mullan MJReduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's diseaseJ Neuroinflammation.(2010 Mar 8)
      7.^Paris D, Beaulieu-Abdelahad D, Abdullah L, Bachmeier C, Ait-Ghezala G, Reed J, Verma M, Crawford F, Mullan MAnti-inflammatory activity of anatabine via inhibition of STAT3 phosphorylationEur J Pharmacol.(2013 Jan 5)
      9.^Buggia-Prevot V, Sevalle J, Rossner S, Checler FNFkappaB-dependent control of BACE1 promoter transactivation by Abeta42J Biol Chem.(2008 Apr 11)
      11.^Peña G, Cai B, Liu J, van der Zanden EP, Deitch EA, de Jonge WJ, Ulloa LUnphosphorylated STAT3 modulates alpha 7 nicotinic receptor signaling and cytokine production in sepsisEur J Immunol.(2010 Sep)
      12.^Haass M, Kübler WNicotine and sympathetic neurotransmissionCardiovasc Drugs Ther.(1997 Jan)
      13.^Jenkins ND, Housh TJ, Johnson GO, Traylor DA, Bergstrom HC, Cochrane KC, Lewis RW Jr, Schmidt RJ, Cramer JTThe effects of anatabine on non-invasive indicators of muscle damage: a randomized, double-blind, placebo-controlled, crossover studyJ Int Soc Sports Nutr.(2013 Jul 22)
      14.^Caturegli P, De Remigis A, Ferlito M, Landek-Salgado MA, Iwama S, Tzou SC, Ladenson PWAnatabine ameliorates experimental autoimmune thyroiditisEndocrinology.(2012 Sep)
      15.^Boyko EJ, Perera DR, Koepsell TD, Keane EM, Inui TSEffects of cigarette smoking on the clinical course of ulcerative colitisScand J Gastroenterol.(1988 Nov)
      16.^Calabrese E, Yanai H, Shuster D, Rubin DT, Hanauer SBLow-dose smoking resumption in ex-smokers with refractory ulcerative colitisJ Crohns Colitis.(2012 Aug)
      19.^Bencherif M, Lippiello PM, Lucas R, Marrero MBAlpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseasesCell Mol Life Sci.(2011 Mar)
      20.^Paris D, Beaulieu-Abdelahad D, Mullan M, Ait-Ghezala G, Mathura V, Bachmeier C, Crawford F, Mullan MJAmelioration of experimental autoimmune encephalomyelitis by anatabinePLoS One.(2013)